| Evaluation of irritation and sensitisation of two 50 microg/day oestrogen patches. | |
| | |
MedLine Citation:
|
PMID: 12468134 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To comparatively assess the irritation and sensitisation of the Estradot transdermal oestrogen patch, in healthy postmenopausal women, using the Menorest transdermal oestrogen patch, as a comparator. METHODS: In an open-label, single-centre, randomised, active-treatment, within-patient controlled study, 208 healthy postmenopausal women, age range 40-70 years, received and completed simultaneous treatment with a 5 cm(2) (50 microg/day) oestradiol patch (Estradot) and a 14.5 cm(2) (50 microg/day) oestradiol patch (Menorest). The treatment was given for 72 h, then 96 h, for eight successive applications during an induction phase, and for 72 h during a challenge phase. There was a 14-day resting period between phases. Skin irritation (measured by erythema on a scale of 0-4), topical sensitisation, patch adherence and local skin reaction, were assessed and recorded immediately before or after removal of each patch, as appropriate. RESULTS: Most patients experienced a significant difference in irritation with Menorest than with Estradot (P < 0.0001) at the end of the induction phase. Patch loss was also significantly higher for Menorest as compared to Estradot (P = 0.0253) at the end of the induction phase. Most incidences of erythema were classified as slight (score of 1), and there was no significant difference in the percentage of topical sensitisation, or in the incidence of local skin reactions between Estradot and Menorest. Patch loss was low for both systems. CONCLUSIONS: Estradot demonstrates reduced skin irritation, superior adhesion and a lower rate of patch loss compared to Menorest. |
| | |
Authors:
|
John Toole; Stewart Silagy; Anita Maric; Barb Fath; Erhard Quebe-Fehling; Patricia Ibarra de Palacios; Liane Laurin; Monique Giguere |
Related Documents
:
|
3399294 - Systemic candidiasis: cutaneous manifestations in low birth weight infants. 9819704 - Diffuse leukodystrophy in an infant with cytochrome-c oxidase deficiency. 9639644 - Infantile myofibromatosis: a rare presentation with intussusception. 16243984 - The optimal depth of central venous catheter for infants less than 5 kg. 20651694 - Is the newborn individualized developmental care and assessment program (nidcap) effect... 15464354 - Timing in the baby brain. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Maturitas Volume: 43 ISSN: 0378-5122 ISO Abbreviation: Maturitas Publication Date: 2002 Dec |
Date Detail:
|
Created Date: 2002-12-06 Completed Date: 2003-04-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7807333 Medline TA: Maturitas Country: Ireland |
Other Details:
|
Languages: eng Pagination: 257-63 Citation Subset: IM |
Copyright Information:
|
Copyright 2002 Published by Elsevier Science Ireland Ltd. |
Affiliation:
|
Hill Top Research Inc 236 Osborne Street, Suite A Winnipeg, MB, Canada R3L-2W2. vheinrichs@hill-top.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Cutaneous Adult Aged Erythema / chemically induced*, pathology Estradiol / administration & dosage, adverse effects* Estrogen Replacement Therapy* Female Humans Middle Aged Postmenopause Severity of Illness Index Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
50-28-2/Estradiol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hysteroscopic findings in postmenopausal abnormal uterine bleeding: a comparison between HRT users a...
Next Document: Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol...